A
Adam Tracy
Researcher at Broad Institute
Publications - 28
Citations - 3872
Adam Tracy is an academic researcher from Broad Institute. The author has contributed to research in topics: Congenital diaphragmatic hernia & Gene. The author has an hindex of 14, co-authored 28 publications receiving 2318 citations. Previous affiliations of Adam Tracy include Harvard University & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy,Chip Stewart,Andrew Dunford,Jaegil Kim,Atanas Kamburov,Robert A. Redd,Michael S. Lawrence,Michael S. Lawrence,Margaretha G.M. Roemer,Amy Li,Marita Ziepert,Annette M. Staiger,Annette M. Staiger,Jeremiah Wala,Matthew D. Ducar,Ignaty Leshchiner,Ester Rheinbay,Amaro Taylor-Weiner,Caroline A. Coughlin,Julian M. Hess,Chandra Sekhar Pedamallu,Dimitri Livitz,Daniel Rosebrock,Mara Rosenberg,Adam Tracy,Heike Horn,Paul Van Hummelen,Andrew L. Feldman,Brian K. Link,Anne J. Novak,James R. Cerhan,Thomas M. Habermann,Reiner Siebert,Andreas Rosenwald,Aaron R. Thorner,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Rameen Beroukhim,Rameen Beroukhim,Gerald Wulf,German Ott,Scott J. Rodig,Scott J. Rodig,Stefano Monti,Donna Neuberg,Markus Loeffler,Michael Pfreundschuh,Lorenz Trümper,Gad Getz,Gad Getz,Margaret A. Shipp +52 more
TL;DR: A comprehensive genetic analysis of 304 primary DLBCLs identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data to provide a roadmap for an actionableDLBCL classification.
Journal ArticleDOI
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao,Diana Miao,Claire A. Margolis,Claire A. Margolis,Wenhua Gao,Martin H. Voss,Martin H. Voss,Wei Li,Dylan J. Martini,Craig Norton,Dominick Bossé,Stephanie M. Wankowicz,Stephanie M. Wankowicz,Dana Cullen,Christine Horak,Megan Wind-Rotolo,Adam Tracy,Marios Giannakis,Marios Giannakis,F.S. Hodi,Charles G. Drake,Mark W. Ball,Mohamad E. Allaf,Alexandra Snyder,Matthew D. Hellmann,Matthew D. Hellmann,Thai H. Ho,Robert J. Motzer,Robert J. Motzer,Sabina Signoretti,William G. Kaelin,William G. Kaelin,Toni K. Choueiri,Eliezer M. Van Allen,Eliezer M. Van Allen +34 more
TL;DR: Clinical benefit was associated with loss-of-function mutations in the PBRM1 gene, which encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, and may alter global tumor-cell expression profiles to influence responsiveness to immune checkpoint therapy.
Journal ArticleDOI
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu,David Liu,Bastian Schilling,Bastian Schilling,Derek Liu,Derek Liu,Antje Sucker,Elisabeth Livingstone,Livnat Jerby-Arnon,Lisa Zimmer,Ralf Gutzmer,Imke Satzger,Carmen Loquai,Stephan Grabbe,Natalie I. Vokes,Natalie I. Vokes,Claire A. Margolis,Claire A. Margolis,Jake Conway,Jake Conway,Meng Xiao He,Meng Xiao He,Haitham Elmarakeby,Haitham Elmarakeby,Felix Dietlein,Felix Dietlein,Diana Miao,Diana Miao,Adam Tracy,Helen Gogas,Simone M. Goldinger,Jochen Utikal,Jochen Utikal,Christian U. Blank,Ricarda Rauschenberg,Dagmar von Bubnoff,Angela M. Krackhardt,Angela M. Krackhardt,Benjamin Weide,Sebastian Haferkamp,Felix Kiecker,Ben Izar,Ben Izar,Levi A. Garraway,Aviv Regev,Keith T. Flaherty,Annette Paschen,Eliezer M. Van Allen,Eliezer M. Van Allen,Dirk Schadendorf +49 more
TL;DR: In this paper, the authors analyzed a clinically annotated cohort of patients with melanoma treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors.
Journal ArticleDOI
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao,Diana Miao,Claire A. Margolis,Claire A. Margolis,Natalie I. Vokes,Natalie I. Vokes,David Liu,David Liu,Amaro Taylor-Weiner,Amaro Taylor-Weiner,Stephanie M. Wankowicz,Stephanie M. Wankowicz,Dennis Adeegbe,Daniel Keliher,Daniel Keliher,Bastian Schilling,Adam Tracy,Michael Manos,Nicole G. Chau,Glenn J. Hanna,Paz Polak,Scott J. Rodig,Scott J. Rodig,Sabina Signoretti,Sabina Signoretti,Lynette M. Sholl,Lynette M. Sholl,Jeffrey A. Engelman,Gad Getz,Pasi A. Jänne,Robert I. Haddad,Toni K. Choueiri,David A. Barbie,Rizwan Haq,Rizwan Haq,Mark M. Awad,Dirk Schadendorf,Dirk Schadendorf,F. Stephen Hodi,Joaquim Bellmunt,Kwok-Kin Wong,Kwok-Kin Wong,Peter S. Hammerman,Eliezer M. Van Allen,Eliezer M. Van Allen +44 more
TL;DR: This study uniformly analyzed whole-exome sequencing of 249 tumors and matched normal tissue from patients with clinically annotated outcomes to immune checkpoint therapy across multiple cancer types to examine additional tumor genomic features that contribute to selective response.
Journal Article
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu,Bastian Schilling,Derek Liu,Antje Sucker,Elisabeth Livingstone,Livnat Jerby-Amon,Lisa Zimmer,Ralf Gutzmer,Imke Satzger,Carmen Loquai,Stephan Grabbe,Natalie I. Vokes,Claire A. Margolis,Jake Conway,Meng Xiao He,Haitham Elmarakeby,Felix Dietlein,Diana Miao,Adam Tracy,Helen Gogas,Simone M. Goldinger,Jochen Utikal,Christian U. Blank,Ricarda Rauschenberg,Dagmar von Bubnoff,Angela M. Krackhardt,Benjamin Weide,Sebastian Haferkamp,Felix Kiecker,Ben Izar,Levi A. Garraway,Aviv Regev,Keith T. Flaherty,Annette Paschen,Eliezer M. Van Allen,Dirk Schadendorf +35 more
TL;DR: Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of previous anti-CTLA4 therapy, and that tumor mutational burden may not be a strong predictor of response across melanoma subtypes.